Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet — R&D group
Over the past few years we’ve seen a growing exodus of R&D experts out of big biopharma groups and into the rapidly growing ranks of biotech startups. Now, one of the biggest players in the oncology field is getting at least one successful biotech scientist and entrepreneur to make an unusual return trip and come back into the fold of a major research organization.
This morning Bristol-Myers Squibb $BMY put out word that the company had hired Saurabh Saha to run the translation science group for the company, which is responsible for triaging preclinical work of interest and steering the most promising programs toward the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
